Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1061-1080 of 1,743 trials

Reducing Radiation in PET Scans: BELOW Trial

We are studying how to lower the dose of radiopharmaceuticals used in PET scans. This research aims to ensure effective imaging while minimizing radiation exposure for patients.

Cancer>2 yearsSafety phase (I)OncologyOtolaryngology

Multiple Sclerosis: ABP 692 vs. Ocrevus

We are comparing a new treatment called ABP 692 with Ocrevus for people with relapsing-remitting multiple sclerosis. The goal is to see how they differ in effectiveness and safety.

Relapsing-Remitting Multiple Sclerosis>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Fecal Microbiota Transplantation for Blood Cancer Stem Cell Transplant Patients

We are studying whether fecal microbiota transplantation can help prevent complications after stem cell transplants in patients with blood cancers. This trial will assess its effects on survival and quality of life.

Patients Post Allogeneic Stem Cell Transplant>2 yearsEfficacy phase (II)Investigational MedicinesHematologyOncology

Esophageal Adenocarcinoma: The PRESTO Trial

We are studying a combination of durvalumab and chemoradiation to see if it can help preserve the esophagus in patients with early-stage cancer. This trial aims to avoid surgery and assess treatment effectiveness and safety.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Prednisone for Idiosyncratic Hepatotoxicity

We are studying whether prednisone can help reduce liver damage in patients with idiosyncratic hepatotoxicity. The trial will also assess its safety and impact on quality of life compared to a placebo.

Liver Toxicity>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHepatologyInternal Medicine

Advanced Solid Tumors: OATD-02 Treatment

We are evaluating the safety and potential effectiveness of OATD-02 in patients with advanced or metastatic solid tumors who have completed an earlier study. This research aims to understand how well this treatment works in this specific group.

Advanced Solid Tumors>2 yearsSafety phase (I)Post-Trial Drug AccessOncology

Cancer Treatment: Enhancing Radionuclide Therapy with PARP Inhibitors

We are exploring whether adding PARP inhibitors can improve outcomes for patients receiving Peptide Receptor Radionuclide Therapy for cancer. This study aims to see if the combination leads to better treatment results.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsSafety phase (I)Internal MedicineOncology

Juvenile Idiopathic Arthritis: MOVE-JIA Trial

We are comparing two treatment withdrawal strategies for children and adolescents with Juvenile Idiopathic Arthritis in remission. The goal is to see which method better prevents disease flares compared to ongoing stable treatment.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Long-Term Follow-Up of Adoptive Cell Therapies

We are monitoring individuals who received genetically modified cell treatments to check for any delayed side effects and how long these cells remain in the body. This study aims to ensure safety and understand the treatment's long-term effects.

Myxoid LiposarcomaMultiple MyelomaSynovial Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Allopurinol for Brain Protection in Newborns with Heart Disease

We are studying whether allopurinol can help reduce brain injury in newborns with critical congenital heart disease during and after cardiac surgery. This trial will also assess its effects on brain and heart function, as well as overall development.

Brain Injury in Neonates with Congenital Heart Disease>2 yearsConfirmation phase (III)Standard MedicinesCardiologyNeurologyPediatrics

Advanced Solid Tumors: PM534 Treatment Study

We are testing a new drug called PM534 in patients with advanced solid tumors. The goal is to learn more about its safety and how it may work in treating this condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

HPV Vaccination After Cervical Lesion Treatment

We are studying whether a secondary HPV vaccination helps women over 45 who have been treated for high-grade cervical lesions achieve HPV-negative status and reduce the risk of recurrence or cancer.

High-Grade Cervical Intraepithelial Lesions>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Acute Myeloid Leukemia: Sulfasalazine with Chemotherapy

We are studying the addition of sulfasalazine to standard chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. The goal is to evaluate safety and effectiveness compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Cryptogenic Stroke: STOP Trial on Blood Thinners

We are studying whether stopping blood thinners is as safe as continuing them for young people after a stroke with no known cause. This research may help understand the best approach to prevent future heart problems.

Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Small Cell Lung Cancer: BI 764532 Dosing Study

We are testing different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3. This study aims to find the most effective dose for these specific cancers.

Small Cell Lung Carcinoma>2 yearsSafety phase (I)Oncology

Outpatient Surgery: Dexmedetomidine Study

We are examining how dexmedetomidine affects blood flow and heart function in patients undergoing scheduled outpatient surgery. This research may help improve anesthesia practices.

Induction of Anesthesia>2 yearsConfirmation phase (III)Internal MedicineOtolaryngology